Analyst Reco. Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Real-time Estimate Cboe BZX Other stock markets 16:05:42 02/05/2024 BST			5-day change	1st Jan Change
45.63 ^USD	+1.29%		+8.39%	+28.84%

04-17	Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing	MT
03-26	Crinetics Pharmaceuticals Insider Sold Shares Worth $1,433,675, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing	04-17	MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $664,763, According to a Recent SEC Filing	03-22	MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $2,648,150, According to a Recent SEC Filing	03-22	MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $449,793, According to a Recent SEC Filing	03-21	MT
JMP Securities Adjusts Price Target on Crinetics Pharmaceuticals to $80 From $60, Maintains Market Outperform Rating	03-20	MT
Oppenheimer Raises Crinetics Pharmaceuticals Price Target to $55 From $54, Maintains Outperform Rating	03-20	MT
JonesTrading Raises Crinetics Pharmaceuticals' Price Target to $56 From $52, Maintains Buy Rating	03-20	MT
HC Wainwright Raises Crinetics Pharmaceuticals Price Target to $60 From $50, Maintains Buy Rating	03-20	MT
Oppenheimer Adjusts Crinetics Pharmaceuticals Price Target to $54 From $48, Maintains Outperform Rating	03-13	MT
HC Wainwright Adjusts Crinetics Pharmaceuticals Price Target to $50 From $42, Maintains Buy Rating	03-08	MT
Citigroup Initiates Crinetics Pharmaceuticals With Buy Rating, $68 Price Target	03-06	MT
Cantor Fitzgerald Adjusts Price Target on Crinetics Pharmaceuticals to $65 From $50, Maintains Overweight Rating	03-04	MT
Oppenheimer Raises Crinetics Pharmaceuticals Price Target to $48 From $46, Maintains Outperform Rating	02-29	MT
Baird Adjusts Crinetics Pharmaceuticals Price Target to $52 From $45, Maintains Outperform Rating	02-29	MT
Investors got more clues that rate cuts are imminent	12-19
Evercore ISI Adjusts Price Target on Crinetics Pharmaceuticals to $48 From $41, Maintains Outperform Rating	11/09/23	MT
Oppenheimer Adjusts Crinetics Pharmaceuticals Price Target to $46 From $40, Maintains Outperform Rating	11/09/23	MT
Baird Adjusts Crinetics Pharmaceuticals Price Target to $45 From $43, Maintains Outperform Rating	11/09/23	MT
Oppenheimer Initiates Coverage on Crinetics Pharmaceuticals With Outperform Rating, $40 Price Target	31/08/23	MT
HC Wainwright Trims Price Target on Crinetics Pharmaceuticals to $33 From $35, Maintains Buy Rating	09/08/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Analyst Reco.

Filters